Compare Fox Corp Class B (FOX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs IDEXX Laboratories, Inc. — how do they compare? Fox Corp Class B trades at $50.95 (market cap $22.28B), while IDEXX Laboratories, Inc. trades at $575.45 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Fox Corp Class B pays a 1.11% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FOX | IDXX | |
|---|---|---|
Market Cap | $22.28B | $43.94B |
Sector | Media | Health |
52-Week High | $67.76 | $766.68 |
52-Week Low | $44.39 | $514.61 |
Enterprise Value | $26.25B | $44.84B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOX) trades at $51.06, up 3.15% with strong recent earnings beats. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, the company delivered robust 2025 results with $16.3B revenue and $2.26B net income, supported by improved cash flow generation. Recent news highlights Fox's strategic positioning in streaming and advertising growth.
Fox presents a compelling value opportunity with reasonable valuation multiples (P/E 13.26, P/S 1.39) and consistent earnings outperformance. However, technical weakness and competitive pressures in media streaming require monitoring. Analyst consensus leans positive with 42.86% buy ratings, though execution risks in the Roku integration and advertising market volatility remain key considerations.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
